EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer

Xingpeng Wang, Kaiyue Wang, Baiyang Huang, Jiarui Zhao, Min Li, Jingyu Zhu, Jing Xu, Chaoran Zhu, Zihan Liu, Xiaohan Wang, Menglin Bai, Xue Meng iD und 3 weitere

Therapeutic Advances in Medical Oncology · 2026-08 · 18

DOI: 10.1177/17588359261472331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 04.08.2026. Verfasst von Xingpeng Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Shandong Second Medical University, Weifang, China. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal perioperative treatment strategy for driver gene-positive non-small cell lung cancer (NSCLC) remains unclear.

Objectives

To compare the prognostic outcomes of different perioperative strategies for patients with resectable driver gene-positive NSCLC.

Design

Multicenter retrospective observational cohort study.

Methods

We retrospectively evaluated patients with resectable AJCC 8th clinical stage II–IIIB driver gene-positive NSCLC who underwent neoadjuvant therapy or upfront surgery with adjuvant targeted therapy (US + ATT) at two institutions between 2021 and 2023. Treatment was classified as neoadjuvant targeted therapy (NTT), neoadjuvant chemoimmunotherapy (NCIT), neoadjuvant chemotherapy (NCT), or US + ATT. The primary endpoints were event-free survival (EFS) and overall survival (OS). Survival was estimated using the Kaplan–Meier method and compared with the log-rank test.

Results

In total, 290 patients were included; the median follow-up was 31.2 months. Compared with NCT, NCIT was associated with longer EFS ( p = 0.048) and a nonsignificant favorable OS trend ( p = 0.135). NCIT also achieved higher pathological complete response (29.8% vs 4.9%) and major pathological response (MPR; 52.1% vs 16.4%) rates and comparable R0 resection rates (96.8% vs 93.4%). Survival outcomes were comparable between NCIT and NCT for the epidermal growth factor receptor (EGFR)-mutant subgroup, but NTT showed better EFS ( p = 0.093), without an OS advantage. NTT + chemotherapy achieved superior EFS ( p = 0.038) and favorable OS trend ( p = 0.146) versus NCT alone and longer EFS versus NTT alone ( p = 0.062). Postoperative ATT did not confer survival advantage over no ATT in the NTT + chemotherapy subgroup. MPR to NCIT correlated with improved EFS ( p = 0.001) and OS ( p = 0.009), while MPR to NTT correlated with improved EFS ( p = 0.049).

Conclusion

NCIT was associated with improved EFS in resectable driver gene-positive NSCLC, although a corresponding OS improvement was not observed. NTT + chemotherapy may offer better prognosis than NCT alone in EGFR‑mutant NSCLC.

Schlagwörter

Stichwörter der Autor:innen

event-free survivalneoadjuvantnon-small cell lung canceroverall survivalperioperative

Autor:innen und Institutionen

  • School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, No. 440, Jiyan Road, Jinan, Shandong 250117, China.

ORCID-Profile: Xue Meng, Jinming Yu, Guoxin Cai

Zitieren

APA

Wang, X., Wang, K., Huang, B., Zhao, J., Li, M., Zhu, J., Xu, J., Zhu, C., Liu, Z., Wang, X., Bai, M., Meng, X., Yu, J., Wang, C., & Cai, G. (2026). Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261472331

Vancouver

Wang X, Wang K, Huang B, Zhao J, Li M, Zhu J, et al. Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261472331

BibTeX
@article{Wang2026,
  author = {Wang, Xingpeng and Wang, Kaiyue and Huang, Baiyang and Zhao, Jiarui and Li, Min and Zhu, Jingyu and Xu, Jing and Zhu, Chaoran and Liu, Zihan and Wang, Xiaohan and Bai, Menglin and Meng, Xue and Yu, Jinming and Wang, Chenggang and Cai, Guoxin},
  title = {Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261472331}
}
Kostenlos starten →